Adma Biologics (ADMA) Cash from Operations (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Cash from Operations data on file, last reported at 35639000.0 in Q4 2025.

• Quarterly Cash from Operations fell 29.03% year-over-year to 35639000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 50396000.0 (down 57.53% YoY) and the FY2025 annual result came in at 50396000.0, down 57.53% from the prior year.
• Cash from Operations advanced to 35639000.0 in Q4 2025, from 13293000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 50216000.0 in Q4 2024 to a low of 33465250.0 in Q4 2021.
• A 5-year average of 299550.0 and a median of 6719029.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations soared 853.36% — and 2025, when it plunged 787.06%.
• Tracing ADMA's Cash from Operations over 5 years: stood at 33465250.0 in 2021, then jumped by 77.95% to 7379058.0 in 2022, then jumped by 338.47% to 17597000.0 in 2023, then soared by 185.37% to 50216000.0 in 2024, then retreated by 29.03% to 35639000.0 in 2025.
• The last three Cash from Operations figures came in at 35639000.0 (Q4 2025), 13293000.0 (Q3 2025), and 21139000.0 (Q2 2025), per Business Quant data.